NPCE News and Press, Neuropace Inc.

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financial results for the fourth quarter of 2025 after market close on Tuesday, March 3, 2026. The company’s management will webcast a c...

2026-01-27 06:15:11 ET H.C. Wainwright analyst issues BUY recommendation for NPCE on January 27, 2026 11:04AM ET. The previous analyst recommendation was Buy. NPCE was trading at $16.23 at issue of the analyst recommendation. The overall analyst consensus : BUY. Curr...

2026-01-14 19:46:01 ET NeuroPace, Inc. (NPCE) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 6:00 PM EST... Read the full article on Seeking Alpha For further details see: NeuroPace, Inc. (NPCE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transc...

2026-01-13 07:39:01 ET More on NeuroPace NeuroPace, Inc. (NPCE) Q3 2025 Earnings Call Transcript NeuroPace raises 2025 revenue and gross margin guidance amid record RNS growth and DIXI wind-down NeuroPace GAAP EPS of -$0.11 beats by $0.09, revenue of $27.4M beats by ...

-- Revenue expected to be approximately $100.0 million in FY 2025, representing growth of 25%-- --Revenue expected to be approximately $26.6 million in Q4 2025, representing growth of 24%-- -- 2026 guidance assumes 20% to 22% growth in core RNS revenue from existing indicati...

NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 44th Annual J.P. Morgan Healthcare Conference at 3:00pm PT on Wednesday, January 14, 2026, in San Francisco, CA. ...

-- Submission supported by positive preliminary 18-month NAUTILUS data in patients with drug-resistant idiopathic generalized epilepsy (IGE) and generalized tonic-clonic (GTC) seizures -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of peo...

-- First randomized controlled trial of neuromodulation in drug-resistant idiopathic generalized epilepsy (IGE) -- -- 18-month data show a 77% median reduction in generalized tonic-clonic (GTC) seizures, supporting forthcoming PMA supplement submission -- -- Remains on track to su...

--Data presentations to feature 18-month NAUTILUS results and new Post Approval Study (PAS) analyses on GTC seizure reduction-- --RNS ® System to be featured in over 80 scientific presentations and posters, the most of any neuromodulation therapy-- NeuroPace, Inc. (Na...

--Physician Fee Schedule (PFS) final rule substantially increases reimbursement for RNS neurostimulator implantation and replacement procedures-- --CY 2026 Outpatient Prospective Payment System (OPPS) Final Rule moves RNS replacement procedures to highest-paying neurostimulator APC-- ...